Arvinas Appoints Kelly Page as Senior Vice President Global Head of Oncology Strategy and Program Leadership Arvinas NASDAQARVN

NEW HAVEN, Conn., April 03, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. ARVN, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kelly Page has joined the company as Senior Vice President, Global Head of Oncology Strategy and Program Leadership. “Kelly brings significant experience in the development of new oncology therapies from R&D through commercialization,” said John Houston, Ph.D., Arvinas President and Chief Executive Officer. “We are pleased to welcome her to our Executive Committee and look forward to her valuable insight as we continue on our journey to become a late-stage…